Anti-Mouse PD-L1 (CD274)

Pricing & Details

  
Product Type
Polyclonal Antibody
Alternate Names
CD274, B7-H1, B7-H, MGC142294, MGC142296, PD-L1, PDCD1L1, PDCD1LG1, PDL1
Applications
ELISA Indirect
,
FC
,
IHC FFPE
,
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
B557-25 µg
25 µg
$179.00
In stock
B557-100 µg
100 µg
$385.00
In stock
  

Antibody Details

Reactivity Species
Mouse
Host Species
Goat
Immunogen
recombinant mouse PD-L1/B7-H1 (Phe19-Thr238 Accession # Q9EP73)
Endotoxin Level
<1.0 EU/µg as determined by the LAL method
Formulation
This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Storage and Handling
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Applications and Recommended Usage ?
(Quality Tested by Leinco)
Indirect ELISA: This antibody can be used in an indirect detection ELISA at 0.5 - 1.0 µg/ml with a suitable second step reagent such as PN:G505. The detection sensitivity of this indirect ELISA for Mouse B7-H1 is approximately 0.3 ng/well. In this format, this antibody shows approximately 20% cross-reactivity with rhB7-H1.
IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 2-15 µg/ml. The recommended secondary antibody for IHC is PN:G505. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.
Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing B7-H1. A suggested method would be to stain cells expressing B7-H1 with 3-10 µg per 1 x 106 cells in a total staining volume of 100 µl followed by PN:G641.
Western Blotting: To detect Mouse B7-H1 this polyclonal antibody can be used at a concentration of 0.1-0.2 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as PN:G505 and a chromogenic substrate such as PN:T343. The detection limit for Mouse B7-H1 is 5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:B526.

Description

Specificity
Goat Anti-Mouse B7-H1 recognizes Mouse B7-H1. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
Antigen Distribution
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Antigen Details

Protein
PD-L1
PubMed
B7-H1+AND+Mouse
NCBI Gene Bank ID
Indirect Elisa Protocol
Flow Cytometry
IHC
General Western Blot Protocol
  
Products are for research use only. Not for use in diagnostic or therapeutic procedures.